메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한뇌졸중학회 대한뇌졸중학회지 대한뇌졸중학회지 제19권 제2호
발행연도
2017.1
수록면
205 - 212 (8page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background and Purpose Recombinant tissue plasminogen activator (rtPA) is one of the proventherapies that improve the outcome of patients with acute ischemic stroke (AIS). In 2009, theMinistry of Health and Welfare, Executive Yuan, Republic of China, launched the project “HospitalEmergent Capability Accreditation by Level-Stroke (HECAL-Stroke)” to improve AIS treatment inTaiwan. The current study was performed to determine whether the project launched by thegovernment was effective in promoting rtPA therapy among AIS patients. Methods All participating hospitals were verified and designated as “heavy duty (HD),” “moderateduty (MoD),” or “medium duty (MeD)” according to the stroke center criteria. Four annual indices(rates of treatment, protocol adherence, in-time treatment, and complications) were recorded from2009 to 2014 as outcome measures. The data were analyzed using the χ2 test for significance. Results The number of certified hospitals progressively increased from 74 to 112 during the 6-yearperiod and finally consisted of 33 HD, 9 MoD and 70 MeD hospitals in 2014. The annualintravenous rtPA treatment rate increased significantly from 3.0% in 2009 to 4.5% in 2014. Theprotocol adherence rates were 95.7% in the HD group, 92.4% in the MoD group and 72.8% in theMeD group. The annual in-time treatment rate significantly improved from 26.0% in 2009 to60.1% in 2014. The overall symptomatic intracranial hemorrhagic rate after rtPA treatment was8.6%. Conclusions Initiation of the HECAL-Stroke project by the government significantly improved rtPAtreatment in Taiwan.

목차

등록된 정보가 없습니다.

참고문헌 (22)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0